NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Collections About News Help Login
Back to Results
Thioaptamer Diagnostic System (TDS)AM Biotechnologies, LLC, in partnership with Sandia National Laboratories, has developed a diagnostic device that quickly detects sampled biomarkers. The TDS quickly quantifies clinically relevant biomarkers using only microliters of a single sample. The system combines ambient-stable, long shelf-life affinity assays with handheld, microfluidic gel electrophoresis affinity assay quantification technology. The TDS is easy to use, operates in microgravity, and permits simultaneous quantification of 32 biomarkers. In Phase I of the project, the partners demonstrated that a thioaptamer assay used in the microfluidic instrument could quantify a specific biomarker in serum in the low nanomolar range. The team also identified novel affinity agents to bone-specific alkaline phosphatase (BAP) and demonstrated their ability to detect BAP with the microfluidic instrument. In Phase II, AM Biotech expanded the number of ambient affinity agents and demonstrated a TDS prototype. In the long term, the clinical version of the TDS will provide a robust, flight-tested diagnostic capability for space exploration missions.
Document ID
20160005386
Acquisition Source
Glenn Research Center
Document Type
Other
Authors
Yang, Xianbin (AM Biotechnologies, LLC Houston, TX, United States)
Date Acquired
April 26, 2016
Publication Date
August 1, 2015
Publication Information
Publication: An Overview of SBIR Phase 2 Physical Sciences and Biomedical Technologies in Space
Subject Category
Aerospace Medicine
Technology Utilization And Surface Transportation
Man/System Technology And Life Support
Distribution Limits
Public
Copyright
Work of the US Gov. Public Use Permitted.

Related Records

IDRelationTitle20150018401Collected WorksAn Overview of SBIR Phase 2 Physical Sciences and Biomedical Technologies in Space
No Preview Available